Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Implementing Regs Open For Comment Until October

This article was originally published in The Pink Sheet Daily

Executive Summary

Proposed rules for Title I (Part D drug benefit) and Title II (Medicare Advantage) of the Medicare Modernization Act are unveiled at an HHS press conference. Final regs will be done by early 2005, "if not sooner," CMS Administrator McClellan says.

You may also be interested in...



Medicare Rx Final Regs Retain CMS Right To Plans’ Drug Price Information

Agency releases final rules implementing Title I and II of the Medicare Modernization Act. CMS’ authority to evaluate data on drug prices negotiated by Medicare prescription drug plans does not violate the “non-interference” provision of MMA, reg states. Drug price reviews will be “rare,” CMS says.

Medicare Rx Final Regs Retain CMS Right To Plans’ Drug Price Information

Agency releases final rules implementing Title I and II of the Medicare Modernization Act. CMS’ authority to evaluate data on drug prices negotiated by Medicare prescription drug plans does not violate the “non-interference” provision of MMA, reg states. Drug price reviews will be “rare,” CMS says.

Medicare Rx Regs To Be Issued Jan. 21

The Centers for Medicare & Medicaid Services will issue its final implementing regulations for the Medicare prescription drug program Jan. 21

Related Content

Topics

UsernamePublicRestriction

Register

PS060121

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel